Clinical and Translational Neurophotonics 2019 2019
DOI: 10.1117/12.2508557
|View full text |Cite
|
Sign up to set email alerts
|

Correlation between PET-derived cerebral amyloid status and retinal image features using a hyperspectral fundus camera

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
1
1
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…On fundus photography, several vascular abnormalities had been reported in AD, such as venular narrowing, diminished vascular branching, increased tortuosity, and decreased arterial fractal dimension (19,(26)(27)(28)(29) leading to the recent development of retinal photography-based deep learning algorithms to cost-effectively screen for AD in community settings (30,31). Furthermore, retinal vascular tortuosity was proposed to improve the detection of the cerebral amyloid status as determined by 8F-florbetaben PET (32). Amyloid β-protein (Aβ) is an early core biomarker of AD, a prerequisite for AD diagnosis, and the target of AD-specific therapies (33), including the recently approved anti-Aβ monoclonal antibodies that bind with high affinity to Aβ plaque and/or soluble protofibrils (34,35).…”
Section: Introductionmentioning
confidence: 99%
“…On fundus photography, several vascular abnormalities had been reported in AD, such as venular narrowing, diminished vascular branching, increased tortuosity, and decreased arterial fractal dimension (19,(26)(27)(28)(29) leading to the recent development of retinal photography-based deep learning algorithms to cost-effectively screen for AD in community settings (30,31). Furthermore, retinal vascular tortuosity was proposed to improve the detection of the cerebral amyloid status as determined by 8F-florbetaben PET (32). Amyloid β-protein (Aβ) is an early core biomarker of AD, a prerequisite for AD diagnosis, and the target of AD-specific therapies (33), including the recently approved anti-Aβ monoclonal antibodies that bind with high affinity to Aβ plaque and/or soluble protofibrils (34,35).…”
Section: Introductionmentioning
confidence: 99%